Developmental neurogenetic diseases can only be studied, and potentially treated, once systems to predictably deliver and express genes in neuronal cells are developed. We will utilize herpes simplex virus (HSV) as a vector for expressing genes in neuronal cells. This human DNA virus, for which about 90% of the U.S. population is seropositive, forms latent infections which persist for the lifetime of the individual. Using II$V derived vectors, we will study the nervous system component of a lysosomal storage disease. Lysosomal storage in neurons results in severe mental retardation in most children with these diseases. Specifically, we will use a beta-glucuronidase-negative-mouse (gus(mps)/gus(mps), with mucopolysaccharidosis (MPS) type VII (Sly disease), as an animal model. During the previous grant period we inserted a beta-glucuronidase gene into HSV- l, under control of the only viral promoter that is active during latency. We demonstrated that the recombinant vector could move from the periphery to the central nervous system. By using this promoter we achieved long term expression of the corrected gene in the nervous system of diseased mice. We now wish to continue our studies by examining the factors that increase GUSB activity in neuronal cells, and increase the number of corrected cells to bring vector correction to a level that will change the clinical disease. We will develop a simple system for inserting genes into HSV in order to increase our capacity to generate recombinant viruses for gene transfer studies. This will accelerate the development of effective vectors by increasing the number of design variations that can be tested. The goal of these studies is to address the problem of treatment of neurogenetic diseases by developing a method of expressing genes in the nervous system in vivo using a ubiquitous human virus. These studies will also provide a method for studying gene regulation in neuronal cells in vivo using the state of the art techniques of molecular biology.

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Research Project (R01)
Project #
2R01NS029390-04A1
Application #
2267565
Study Section
Diabetes, Endocrinology and Metabolic Diseases B Subcommittee (DDK)
Project Start
1991-04-07
Project End
1998-11-30
Budget Start
1994-12-16
Budget End
1995-11-30
Support Year
4
Fiscal Year
1995
Total Cost
Indirect Cost
Name
Wistar Institute
Department
Type
DUNS #
042250712
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Liu, Wenpei; Griffin, Gerald; Clarke, Trena et al. (2015) Bilateral single-site intracerebral injection of a nonpathogenic herpes simplex virus-1 vector decreases anxiogenic behavior in MPS VII mice. Mol Ther Methods Clin Dev 2:14059
Volcy, Ketna; Fraser, Nigel W (2013) DNA damage promotes herpes simplex virus-1 protein expression in a neuroblastoma cell line. J Neurovirol 19:57-64
Simonato, Michele; Bennett, Jean; Boulis, Nicholas M et al. (2013) Progress in gene therapy for neurological disorders. Nat Rev Neurol 9:277-91
Husain, T; Passini, M A; Parente, M K et al. (2009) Long-term AAV vector gene and protein expression in mouse brain from a small pan-cellular promoter is similar to neural cell promoters. Gene Ther 16:927-32
Wolfe, John H (2009) Gene therapy in large animal models of human genetic diseases. Introduction. ILAR J 50:107-11
Berges, Bradford K; Wolfe, John H; Fraser, Nigel W (2007) Transduction of brain by herpes simplex virus vectors. Mol Ther 15:20-9
Berges, Bradford K; Yellayi, Srikanth; Karolewski, Brian A et al. (2006) Widespread correction of lysosomal storage in the mucopolysaccharidosis type VII mouse brain with a herpes simplex virus type 1 vector expressing beta-glucuronidase. Mol Ther 13:859-69
Berges, B K; Wolfe, J H; Fraser, N W (2005) Stable levels of long-term transgene expression driven by the latency-associated transcript promoter in a herpes simplex virus type 1 vector. Mol Ther 12:1111-9
Kang, Wen; Mukerjee, Ruma; Fraser, Nigel W (2003) Establishment and maintenance of HSV latent infection is mediated through correct splicing of the LAT primary transcript. Virology 312:233-44
Heuer, Gregory G; Passini, Marco A; Jiang, Kanli et al. (2002) Selective neurodegeneration in murine mucopolysaccharidosis VII is progressive and reversible. Ann Neurol 52:762-70

Showing the most recent 10 out of 25 publications